Insulin Manufacturing

Diabetes affects over 1.1 million people in Syria, yet domestic insulin production is nonexistent. This project proposes the establishment of a GMP-certified insulin manufacturing facility capable of producing multiple insulin types—including regular, NPH, and analog formulations—to address local demand and export to neighboring markets.